Cargando…
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal antibodies for human epidermal growth factor receptor-2 (HER2)-enriched; and general chemotherapy for triple negative breast...
Autores principales: | Gandhi, Nishant, Das, Gokul M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406734/ https://www.ncbi.nlm.nih.gov/pubmed/30691108 http://dx.doi.org/10.3390/cells8020089 |
Ejemplares similares
-
Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer
por: Chu, Pei-Yi, et al.
Publicado: (2019) -
Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer
por: Gandhi, Nishant, et al.
Publicado: (2021) -
Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer
por: Nagayama, Yuji, et al.
Publicado: (2022) -
Pathological implications of metabolic reprogramming and its therapeutic potential in medulloblastoma
por: Marabitti, Veronica, et al.
Publicado: (2022) -
Photoreceptor metabolic reprogramming: current understanding and therapeutic implications
por: Pan, Warren W., et al.
Publicado: (2021)